| Jonathan M. N. Rigby |
Jonathan M. N. Rigby was the founder of Zogenix, Inc. (founded in 2006) where he held the title of Vice President-Business Development from 2006 to 2010. He is currently the Group Chief Executive Officer & Director at Revolo Biotherapeutics Ltd. (since 2020). He is also the Chairman at the Association of Needle-Free Injection Manufacturers (since 2010), Chairman & Chief Business Officer at BioPlus Acquisition Corp. (since 2021), Director at Oncolytics Biotech, Inc. (since 2022), Director at Thermalin, Inc., and Director at ImmunoMolecular Therapeutics, Inc. (since 2021). Mr. Rigby's former positions include President, Chief Executive Officer & Director at SteadyMed Therapeutics, Inc. (from 2011 to 2019), President, Chief Executive Officer & Director at SteadyMed Ltd., Chairman at CollPlant Biotechnologies Ltd. (in 2019), Independent Non-Executive Director at Xeris Pharmaceuticals, Inc. (from 2016 to 2019), Vice President-Business Development at Aradigm Corp. (from 2002 to 2006), and Head-Business Development & Sales at Respironics Ltd. (from 1995 to 2002). Mr. Rigby's education includes an undergraduate degree from The University of Sheffield and an MBA from the University of Portsmouth. |
| Ross Haghighat |
Ross Haghighat is the founder of CoreTek, Inc. (founded in 1994), Aduro BioTech, Inc. (founded in 2008), Triton Systems, Inc. (founded in 1992), and FRX Polymers, Inc. (founded in 2007). He is currently the Co-Chief Executive Officer & Director at Epiphany Technology Acquisition Corp., Executive Chairman at Avertix Medical Systems, Inc., Chairman at FRX Innovations, Inc., Non-Executive Director at Emefcy Ltd., Director at SI2 Technologies, Inc., Director at ACT Ltd., Non-Executive Director at Fluence Corp. Ltd., Director at Electriq Global Ltd., Director, Chief Executive & Financial Officer at Enterprise 4.0 Technology Acquisition Corp., Managing Partner at Newburyport Partners Pty Ltd., Chief Executive & Financial Officer at BioPlus Acquisition Corp., and Partner at Jasper Capital Partners. He has held former positions as Chairman at Respiri Ltd. (2010-2014), Director at Sensera, Inc., Director at Mavatar Technologies, Inc., Independent Non-Executive Director at Emefcy Group Ltd., Director at Redrock Biometrics, Inc., Independent Director at CITIC Capital Acquisition Corp., Independent Director at Chinook Therapeutics, Inc. (2009-2023), and Senior Engineer at Foster-Miller, Inc. He holds an MBA from Boston College and undergraduate and graduate degrees from Rutgers State University of New Jersey (conferral dates: 1985 and 1986). |
| Stephen A. Sherwin |
Stephen A. Sherwin was the founder of Ceregene, Inc. (founded in 2001) where he served as Chairman from 2001 to 2013. He is also the founder of Abgenix, Inc. Dr. Sherwin's current job positions include Lead Independent Director at Neurocrine Biosciences, Inc. (since 1999), Independent Director at Biogen, Inc. (since 2010), Director at Avertix Medical Systems, Inc., Director at Rheos Medicines, Inc., Independent Director at BioPlus Acquisition Corp. (since 2021), Professor at The University of California, San Francisco, Member of the American Society of Clinical Oncology, Inc., Member of the American Association for Cancer Research, Advisory partner at Third Rock Ventures LLC (since 2016), Member-Supervisory Board at Biogen GmbH (since 2010), and Clinical Professor at the University of California. Dr. Sherwin's former job positions include Chairman & Chief Executive Officer at Cell Genesys, Inc. (1990-2009), Chairman at Biotechnology Innovation Organization (2001-2014), Independent Director at Vical, Inc. (2013-2015), Director at ANI Pharmaceuticals, Inc. (2009-2013), Independent Director at Rigel Pharmaceuticals, Inc. (2000-2017), Independent Director at Aduro BioTech, Inc. (2015-2020), Director at Biogen Idec New Ventures, Inc., Independent Director at Verastem, Inc. (2013-2016), Independent Director at BioNTech US, Inc. (2015-2020), and Vice President-Clinical Research at Genentech, Inc. (1983-1990). Dr. Sherwin's education includes an undergraduate degree from Yale University and a doctorate degree from Harvard Medical School. Dr. Sherwin is also the founder of Abgenix, Inc... |
| Shawn Mikael Cross |
Shawn Mikael Cross is an Independent Director at Cyclo Therapeutics, Inc. and BioPlus Acquisition Corp. He previously served as the Chairman & Chief Executive Officer at GT Biopharma, Inc., Applied Molecular Transport, Inc., and Managing Director at Citizens JMP Securities LLC and Wells Fargo Securities LLC. He also held positions as Principal at Deutsche Bank Securities, Inc., Deutsche Bank AG, Thomas Weisel Partners LLC, Alex. Brown & Sons, Inc., and the University of Washington Medical Center. Mr. Cross completed his undergraduate degree at the University of California, Los Angeles and holds an MBA from Columbia Business School. |
| Louis G. Lange |
Louis G. Lange founded CV Therapeutics, Inc. in 1990, where he worked as Chairman, CEO & Chief Scientific Officer from 1992 to 2009, Cardiogen Sciences, Inc. in 2014, where he worked as Director from 2014 to 2015, and Rapidscan Pharma Solutions, Inc. in 2010, where he worked as Chairman. Dr. Lange also founded Amygdala Neurosciences, Inc., where he is working as Executive Chairman. Dr. Lange also currently works at InCarda Therapeutics, Inc., as Director, Maverix Biomics, Inc., as Director from 2014, NewAmsterdam Pharma BV, as Non-Executive Director, and various other companies. Dr. Lange also formerly worked at CymaBay Therapeutics, Inc., as Chairman from 2009 to 2015, CardioDx, Inc., as Chairman, Institute for Systems Biology, as Chairman, and various other companies. Dr. Lange received his undergraduate degree from Rochester Christian University, doctorate degree from Harvard University, and doctorate degree from Harvard Medical School. |
| Glen Giovannetti |
Glen Giovannetti is currently serving as a Director at XWPharma Ltd., Revolo Biotherapeutics Ltd., Teon Therapeutics, Inc., and Life Science Cares, Inc. He is also an Independent Director at Enterprise 4.0 Technology Acquisition Corp. He previously worked as a Director at Biotechnology Innovation Organization from 2011 to 2014 and as a Partner at Ernst & Young LLP from 1984 to 2020. He completed his undergraduate degree from Linfield College. |
